Deep Genomics

Life science executive with over 30yrs experience. Has lived and worked in 6…

Brendan led the launch of Deep Genomics in 2015, to address the need for a new data- and AI-driven approach to genetic medicine. He is responsible for ensuring that our machine learning platform rapidly identifies the best drug candidates, and that those candidates move forward for IND-enabling work. Over the past 15 years, he has co-authored over 200 papers on machine learning and genome biology, including over a dozen that appeared in Nature, Science and Cell. His inventions include one of the first deep learning algorithms (1995), factor graphs (1997), a coding method that is used in most telecommunications devices (1999), affinity propagation (2007), and deep learning models of splicing (2015, 2018), protein-DNA/RNA interaction (2015) and polyadenylation (2017). Brendan holds numerous distinctions and is a Professor of Engineering and Medicine at the University of Toronto, a Co-Founder of the Vector Institute for Artificial Intelligence and a Senior Fellow of the Canadian Institute for Advanced Research.

Jason is a Humanist who believes that the Singularity is nearer than we think and that positive futures must be thoughtfully created. He has 7 YoE building models and solutions across the entire ML lifecycle. As a results-driven engineer, Jason has a long track record of identifying and deeply understanding problems, delivering value, and iterating rapidly on lean, fast-moving teams operating in challenging domains. He has spearheaded scientific contributions of his own from ideation to deployment, while also supporting and mentoring ML Scientists with data & platform engineering along the way. Most notably, Jason trained, deployed, and presented a Multi-Agent Reinforcement Learned (MARL) model for autonomous stem cell colony control. The MARL agents, trained in a parallelized In Silico simulation which Jason also built, were successfully deployed Sim2Real to Cellino's biomanufacturing system and are estimated to have doubled production capacity. Additional career highlights also include the training of a ViT decoder from SAM2 Foundation Model embeddings to regressively model cell culture densities, co-inventing a variety of morphological management techniques for stem cell colonies, prototyping a Few-Shot In-Context Learning (ICL) Pluripotency classifier with the GPT-4o Vision Language Model (VLM), designing and building a graph-based cell culture tracking and visualization system, scaling RL systems for billions of products at Wayfair, and founding an Augmented Reality Metaverse startup. Jason is currently seeking another opportunity to build autonomy zero to one on an ambitious team with an incredible vision and strong technical leadership.

Tom Masterson is the Chief Operating Officer at Deep Genomics. Holding responsibility for…

David Johnston, CFO, brings over thirty years of senior financial leadership experience. Currently, David Johnston is principal of dbj consulting LLC, providing fractional CFO services as well as financial and strategic advice to emerging life science companies. He was recently Chief Financial Officer for ImmunoGen, Inc., oncology-focused biotech based in Waltham, MA. During his tenure at ImmunoGen, he led several public offerings and a creative, non-dilutive royalty financing. Before ImmunoGen, David Johnston served as CFO for Aveo Oncology and Genzyme Biosurgery. He led both their initial public offerings and led several strategic initiatives, both on the buy-side and the sell-side. Mr. Johnston earned a B.S. at Washington and Lee University and an MBA at the University of Michigan. David Johnston sat on the board of directors of RAW Art Works, a nonprofit youth arts organization, and Tissue Banks International, one of the most significant eyes and tissue bank nonprofits in the United States.